ACADIA Pharmaceuticals Inc.

NasdaqGS:ACAD 株式レポート

時価総額：US$5.2b

ACADIA Pharmaceuticals 将来の成長

Future 基準チェック /16

ACADIA Pharmaceuticals利益と収益がそれぞれ年間15.5%と10.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16.5% 11.1%なると予測されています。

主要情報

15.5%

収益成長率

11.05%

EPS成長率

Biotechs 収益成長27.2%
収益成長率10.8%
将来の株主資本利益率16.48%
アナリストカバレッジ

Good

最終更新日18 Aug 2026

今後の成長に関する最新情報

分析記事 • Aug 08

Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its quarterly report and things are looking bullish. It was...

Recent updates

分析記事 • Aug 08

Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its quarterly report and things are looking bullish. It was...
ナラティブ更新 • Aug 05

ACAD: Future Upside Will Hinge On Alzheimer Psychosis Remlifanserin Data

ACADIA Pharmaceuticals' analyst fair value estimate has been adjusted to $33.25 from $31.80 as analysts factor in stronger Daybue traction, higher long term profit margin assumptions, and the upcoming Phase 2 remlifanserin readout as key supports for higher price targets across the Street. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a generally constructive tone, with many firms lifting price targets and focusing on execution around Daybue, Nuplazid and the upcoming remlifanserin data.
Seeking Alpha • Jul 27

Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout

Summary Acadia Pharmaceuticals Inc. ended July on a high note. The top line results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis are expected in August-October 2026. Acadia expects its 2026 revenue will be $1.22-$1.28 billion, representing about 16.5% YoY growth. Meanwhile, the average price target for Acadia is $32.8 [from $17 to $45], which implies an upside of about 32.1% from its current stock price. As a result, in my view, Acadia's risk/reward is attractive. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 22

ACAD: Alzheimer’s Psychosis Data Will Test High-Risk Remlifanserin Story

Analysts have raised their average price targets on ACADIA Pharmaceuticals by a few dollars per share into the mid $30s, citing expectations for stronger Daybue and Nuplazid trends, as well as updated views on pipeline assets such as remlifanserin and trofinetide, following recent positive CHMP opinions and study designs. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a mix of optimism around product momentum and caution around execution and drug development risk.
ナラティブ更新 • Jun 17

ACAD: Buy Upgrade And Guidance Reaffirmation Will Drive Upside From Pullback

ACADIA Pharmaceuticals' analyst price target has been trimmed by $1, as analysts recalibrate their models around slightly different long term growth, profitability, and discount rate assumptions reflected in recent research updates. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals shows a mix of caution and optimism, with the modest price target trim sitting alongside more constructive views from bullish analysts who see room for the stock to recover from recent weakness.
ナラティブ更新 • Jun 02

ACAD: Rett And Alzheimer’s Psychosis Milestones Will Shape Balanced Risk Reward

Analysts have nudged their price expectations for ACADIA Pharmaceuticals higher, with the updated fair value estimate moving from about $19.64 to $19.75 per share as they refine assumptions around growth, margins, and future P/E multiples following recent target changes and rating updates on the stock. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals reflects a mix of optimism and caution, with some firms lifting price targets and others trimming expectations or flagging risks.
ナラティブ更新 • May 09

ACAD: Remlifanserin Alzheimer’s Psychosis Readout Will Drive Upside From Undervalued Levels

Analysts recently adjusted their fair value estimate for ACADIA Pharmaceuticals slightly lower to $43.55 from $43.97, reflecting updated assumptions for revenue growth, profitability, and future P/E. This revision also incorporates mixed but generally constructive Street price target updates in the $26 to $37 range, along with several fresh Buy and Outperform ratings.
ナラティブ更新 • Apr 23

ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside

Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.
ナラティブ更新 • Apr 08

ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes

The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.
ナラティブ更新 • Mar 24

ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels

ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.
ナラティブ更新 • Mar 10

ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside

ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.
ナラティブ更新 • Feb 23

ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism

ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.
ナラティブ更新 • Feb 09

ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion

Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.
ナラティブ更新 • Jan 25

ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside

Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.
ナラティブ更新 • Jan 11

ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver

Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.
ナラティブ更新 • Dec 26

ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels

Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.
ナラティブ更新 • Dec 12

ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback

Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.
分析記事 • Nov 13

Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings

Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings recently, the stock hasn't reacted in a...
分析記事 • Nov 09

ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) came out with its quarterly results last week, and we wanted to see how the...
ナラティブ更新 • Sep 26

Global Outreach And Pipeline Programs Will Expand CNS Markets

ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.
ナラティブ更新 • Sep 04

Global Outreach And Pipeline Programs Will Expand CNS Markets

Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.
Seeking Alpha • Feb 13

Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'

Summary Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and DAYBUE, with 2024 revenue projections of $600m-$610m and $340m-$350m respectively, and overall revenues forecast to exceed $1bn in '25. Acadia's promising pipeline, including ACP-204 and ACP-101, and successful marketing campaigns suggest strong future growth potential. Given the company's profitability, robust pipeline, and undervaluation compared to peers, I am upgrading Acadia from "Sell" to "Buy". Read the full article on Seeking Alpha
Seeking Alpha • Nov 27

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Summary NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. Company entered into a worldwide license agreement with Saniona to develop and commercialize SAN711 for the treatment of patients with Essential Tremor; Phase 2 study to be initiated in 2026. Read the full article on Seeking Alpha
Seeking Alpha • Nov 11

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Summary Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. An updated analysis around ACAD stock follows in the paragraphs below. Read the full article on Seeking Alpha

業績と収益の成長予測

NasdaqGS:ACAD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20281,60628331236216
12/31/20271,4311588417120
12/31/20261,27210611723520
6/30/20261,139380146160N/A
3/31/20261,095376114123N/A
12/31/20251,0723916110N/A
9/30/20251,04726199199N/A
6/30/20251,01922288188N/A
3/31/202599622950149N/A
12/31/2024958226157158N/A
9/30/2024929129203203N/A
6/30/2024891318081N/A
3/31/2024814-22464N/A
12/31/2023726-61-2317N/A
9/30/2023632-149-133-93N/A
6/30/2023551-111-74-34N/A
3/31/2023520-146-56-56N/A
12/31/2022517-216-114-114N/A
9/30/2022512-217-113-113N/A
6/30/2022512-205-130-130N/A
3/31/2022493-214-142-142N/A
12/31/2021484-168-127-126N/A
9/30/2021474-192-133-130N/A
6/30/2021463-262-141-136N/A
3/31/2021458-260-155-147N/A
12/31/2020442-282-144-136N/A
9/30/2020419-268-144-138N/A
6/30/2020393-225-139-134N/A
3/31/2020366-238N/A-136N/A
12/31/2019339-235N/A-151N/A
9/30/2019300-248N/A-161N/A
6/30/2019264-268N/A-184N/A
3/31/2019238-276N/A-186N/A
12/31/2018224-245N/A-167N/A
9/30/2018208-249N/A-158N/A
6/30/2018185-252N/A-174N/A
3/31/2018158-256N/A-192N/A
12/31/2017125-289N/A-218N/A
9/30/201793-299N/A-251N/A
6/30/201763-306N/A-242N/A
3/31/201733-309N/A-240N/A
12/31/201617-271N/A-208N/A
9/30/20165-238N/A-182N/A
6/30/20160-206N/A-165N/A
3/31/20160-174N/A-138N/A
12/31/20150-164N/A-122N/A
9/30/20150-147N/A-105N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACADの予測収益成長率 (年間15.5% ) は 貯蓄率 ( 3.7% ) を上回っています。

収益対市場: ACADの収益 ( 15.5% ) US市場 ( 16.9% ) よりも低い成長が予測されています。

高成長収益: ACADの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ACADの収益 ( 10.8% ) US市場 ( 12.9% ) よりも低い成長が予測されています。

高い収益成長: ACADの収益 ( 10.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACADの 自己資本利益率 は、3年後には低くなると予測されています ( 16.5 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/19 11:17
終値2026/08/19 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

ACADIA Pharmaceuticals Inc. 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38

アナリスト機関
null nullBaird
Jack AllenBaird
Joel BeattyBaird